This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | MicrobiomeTrials
← Back to trials NCT02393157
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2015-08-21Est. Completion: 2026-12
Enrollment target: 25 participantsLocations New York Medical College, Valhalla, New York, United States Other microbiome trials you might be interested in Relapsed Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia B-cell Acute Lymphoblastic Leukemia Pediatric Cancer Pediatric ALL, Relapsed Pediatric ALL Pediatric ALL, B Cell Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Pediatric AML R/R AML R/R B-cell ALL
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescen…
Multiple Locations Est. completion Apr 30, 2030
Phase 1
Recruiting
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin …
Duarte, United States Est. completion Jun 30, 2027
Lymphoplasmacytic Lymphoma Waldenstrom Macroglobulinemia
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrut…
Tucson, United States Est. completion Mar 31, 2028